TNF and rheumatoid arthritis: It estimates a significant risk of CIN 2–3 (HR 1.39; 95% CI 1.16–1.66) in women with RA, who do not receive biologic DMARDs (treated with at least two of the following drugs: methotrexate, sulfasalazine, antimalarials, or leflunomide), and a significant risk of CC (HR 2.10, 95% CI 1.04–4.23) in the tumor necrosis factor inhibitor (TNFi) treatment group.